Technology
Health
Biotechnology

Diffusion Pharmaceuticals

$2.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.24 (-9.52%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell DFFN and other stocks, options, ETFs, and crypto commission-free!

About DFFN

Diffusion Pharmaceuticals Inc. Common Stock, also called Diffusion Pharmaceuticals, is a clinical stage company which engages lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, for use in those life threatening conditions in which cellular oxygen deprivation is the basis for significant unmet medical needs. Read More The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Employees
10
Headquarters
Charlottesville, Virginia
Founded
2001
Market Cap
8.51M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
197.97K
High Today
$2.48
Low Today
$2.26
Open Price
$2.48
Volume
75.23K
52 Week High
$11.00
52 Week Low
$1.83

Collections

Technology
Health
Biotechnology
Medical
2018 IPO
US
North America

DFFN Earnings

-$0.90
-$0.62
-$0.34
-$0.06
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 12, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.